Global Human Microbiome Key Developments and Players Human Microbiome Market Research Reports | Page 4
14.6 Aperiomics, Inc.
14.7 Atlas Biomed
14.8 AvidBiotics
14.9 Beckman Coulter / Danaher
14.10 Becton, Dickinson and Company (BD)
14.11 Biocartis Group
14.12 C3J Therapeutics (formerly C3 Jian)
14.13 Crestovo (Finch Therapeutics Group)
14.14 Danaher Corporation
14.15 Eppendorf AG
14.16 Evelo Biosciences
14.17 Evolve Biosystems
14.18 Finch Therapeutics Group
14.19 One Codex
14.20 OpenBiome
14.21 Optibiotix
14.22 OraSure Technologies, Inc.
14.23 Osel, Inc.
14.24 PerkinElmer, Inc. (Pe)
14.25 Pfizer, Inc.
14.26 Phase Genomics
14.27 Proderm IQ
14.28 Prodigest
14.29 Promega Corporation
14.30 PureFlora Inc.
14.31 QIAGEN
14.32 Quay Pharma
14.33 Whole Biome
14.34 Xycrobe Therapeutics, Inc.
14.35 Zymo Research
15 Key Microbiome Developments
15.1 Agreements, Partnerships, Collaborations and Joint Ventures
15.2 Acquisitions & Mergers
15.3 New Product Launch
15.4 Expansions
15.5 Other Key Strategies
List of Tables:
Table 1 Focus Disease Areas for Microbiome Research
Table 2 Microbiome Drug Development Approaches
Table 3 Venture Capital Investments in Microbiome Start-Ups ($ Millions
Table 4 Industry collaborations in Microbiome-based Companies ($ Millions)
Table 5 4D Pharma Pipeline
Table 6 Avidbiotics Pipeline
Table 7 Osel Pipeline
Table 8 Bioinformatic tools for metagenomic datasets analyses
Table 9 Microbiome-based Drugs in Development for Cancer
Table 10 Microbiota Associated with Type 2 Diabetes
TABLE 11 Microbiome-based Drugs in Development for Clostridium Difficile Infection
TABLE 12 Globally Patient Volumes for Microbiome-based Drugs for Type 2 Diabetes, by Company,
through 2024 TABLE 22 Table 13 Globally Market for Microbiome-based Drugs for Type 2 Diabetes, by
Company, through 2024
TABLE 14 Global Prevalence of Clostridium Difficile Infection, through 2024
TABLE 15 Microbiome-based Drugs in Development for Clostridium Difficile Infection
TABLE 16 Globally Market Shares of Microbiome-based Drugs for Clostridium Difficile Infection, by
Company, 2018–2024 (%)
TABLE 17 Globally Patient Volumes for Microbiome-based Drugs for Clostridium Difficile Infection, by
Company, through 2024 (Thousands)
[email protected]